FindTrial
Sign In

PREDNISONE VIATRIS 20 mg

DRUG3 trials

Sponsors

Centre Hospitalier Universitaire De Caen Normandie, Alexion Pharmaceuticals Inc., Centre Hospitalier National D'Ophtalmologie Quinze-Vingts

Conditions

Acute Anterior Ischemic Optic Neuropathy associated with Giant Cell Arteritis in Horton's DiseaseBAG3 Mutation Associated Dilated CardiomyopathyPatients with giant cell arteritis (= Horton’s disease)

Phase 1

A Phase 1/2, Open-Label, Dose Finding Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants with Symptomatic BAG3 Mutation-Associated Dilated Cardiomyopathy
Not yet recruitingCTIS2024-519674-40-00
Alexion Pharmaceuticals Inc.BAG3 Mutation Associated Dilated Cardiomyopathy
Target: 8Updated: 2025-12-12

Phase 2

French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic optic neuropathy associated with giant cell arteritis. (TOCIAION)
Not yet recruitingCTIS2024-519977-20-00
Centre Hospitalier National D'Ophtalmologie Quinze-VingtsAcute Anterior Ischemic Optic Neuropathy associated with Giant Cell Arteritis in Horton's Disease
Target: 58Updated: 2025-01-27

Phase 3

RANDOMIZED, CONTROLLED, OPEN TRIAL OF TWO STANDARDIZED DECLINE SCHEMES, FAST (NORTH AMERICAN) AND SLOW (EUROPEAN) RESPECTIVELY, OF CORTISONE IN GIANT CELL ARTERITIS
Not yet recruitingCTIS2024-518653-41-00
Centre Hospitalier Universitaire De Caen NormandiePatients with giant cell arteritis (= Horton’s disease)
Target: 150Updated: 2025-07-24